We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01234766
Recruitment Status : Active, not recruiting
First Posted : November 4, 2010
Last Update Posted : May 5, 2016
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : June 2014
  Estimated Study Completion Date : December 2020